Cannabinoid-focused biotechnology company Demetrix announced Thursday it secured $50 million in a Series A funding round led by Tuatara Capital. Another investor is Horizons Ventures, which previously led Demetrix's $11 million Series Seed round.
Demetrix aims to develop a technology that would allow producing cannabinoids using baker's yeast. It uses a fermentation technology that speeds up the production of cannabinoids.
Never miss a news story in the cannabis world. Click here to check out Benzinga Cannabis for more.
Demetrix's approach could for the cannabinoid supply chain, which currently relies on plant cultivation and extraction. Aside from CBD and THC, other cannabinoids are present in very low concentrations, which means that it's difficult to produce them on an economical scale.
The company plans to use the recently-raised money to scale its operations and commercialize the first of more than 100 unique cannabinoids.
"We’ve assembled a team of industry veterans, built a scalable technology platform, and are working with global regulatory organizations to quickly commercialize," said Demetrix CEO Jeff Ubersax.
Benzinga's Cannabis Capital Conference heads to Detroit on Aug. 15 -- Click here to learn more!
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Cannabis is evolving—don’t get left behind!
Curious about what’s next for the industry and how to stay ahead in today’s competitive market?
Join top executives, investors, and industry leaders at the Benzinga Cannabis Capital Conference in Chicago on June 9-10. Dive deep into market-shaping strategies, investment trends, and brand-building insights that will define the future of cannabis.
Secure your spot now before prices go up—this is where the biggest deals and connections happen!
